stoxline Quote Chart Rank Option Currency Glossary
Bausch + Lomb Corporation (BLCO)
14.93  -0.16 (-1.06%)    06-21 16:00
Open: 15.08
High: 15.25
Volume: 594,948
Pre. Close: 15.09
Low: 14.78
Market Cap: 5,240(M)
Technical analysis
2024-06-21 4:50:59 PM
Short term     
Mid term     
Targets 6-month :  17.79 1-year :  18.36
Resists First :  15.23 Second :  15.72
Pivot price 15.11
Supports First :  14.44 Second :  12.02
MAs MA(5) :  14.95 MA(20) :  15.12
MA(100) :  15.3 MA(250) :  16.43
MACD MACD :  -0.1 Signal :  0
%K %D K(14,3) :  28.7 D(3) :  27.1
RSI RSI(14): 48
52-week High :  21.95 Low :  13.15
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ BLCO ] has closed above bottom band by 29.8%. Bollinger Bands are 57.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 18 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 15.27 - 15.34 15.34 - 15.42
Low: 14.56 - 14.66 14.66 - 14.75
Close: 14.76 - 14.91 14.91 - 15.05
Company Description

Bausch + Lomb Corporation operates as an eye health company worldwide. It operates through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products, over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions comprising eye allergies, conjunctivitis, and dry eye. The Ophthalmic Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of eye conditions, such as glaucoma, ocular hypertension, and retinal diseases; and contact lenses for therapeutic use. The Surgical segment provides tools and technologies for the treatment of cataracts, and vitreous and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices. The company was founded in 1853 and is headquartered in Vaughan, Canada.

Headline News

Sat, 22 Jun 2024
Little Excitement Around Bausch + Lomb Corporation's (NYSE:BLCO) Revenues - Simply Wall St

Sat, 22 Jun 2024
Quadrature Capital Ltd Raises Stake in Bausch + Lomb Co. (NYSE:BLCO) - Defense World

Thu, 20 Jun 2024
Trend Tracker for (BLCO) - Stock Traders Daily

Wed, 19 Jun 2024
Bausch + Lomb Co. (NYSE:BLCO) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat

Wed, 19 Jun 2024
Bausch + Lomb Co. (NYSE:BLCO) Sees Significant Increase in Short Interest - Defense World

Mon, 17 Jun 2024
Bausch + Lomb Co. (NYSE:BLCO) Sees Large Increase in Short Interest - MarketBeat

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Medical - Instruments & Supplies
Shares Out 351 (M)
Shares Float 41 (M)
Held by Insiders 88.5 (%)
Held by Institutions 10.8 (%)
Shares Short 1,880 (K)
Shares Short P.Month 1,630 (K)
Stock Financials
EPS -0.96
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 18.95
Profit Margin -7.9 %
Operating Margin 1.3 %
Return on Assets (ttm) 1 %
Return on Equity (ttm) -4.7 %
Qtrly Rev. Growth 18 %
Gross Profit (p.s.) 0
Sales Per Share 12.26
EBITDA (p.s.) 1.74
Qtrly Earnings Growth 0 %
Operating Cash Flow 80 (M)
Levered Free Cash Flow -48 (M)
Stock Valuations
PE Ratio -15.56
PEG Ratio 12
Price to Book value 0.78
Price to Sales 1.21
Price to Cash Flow 65.59
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android